Apixaban 5 mg Oral Tablet

DRUG3 trials

Sponsors

Vastra Gotaland Region, Assistance Publique - Hôpitaux de Paris, VarmX B.V.

Conditions

Aortic Valve DiseaseCoagulation DisorderTakotsubo Syndrome

Phase 1

Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

Active, not recruitingNCT06372483

VarmX B.V.Coagulation Disorder

Start: 2024-02-21End: 2026-08-31Updated: 2024-11-18

Phase 3

DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

Not yet recruitingNCT05687448

Assistance Publique - Hôpitaux de ParisAortic Valve Disease

Start: 2025-09-30End: 2029-03-31Target: 1500Updated: 2025-06-12

Phase 4

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

RecruitingNCT04666454

Vastra Gotaland RegionTakotsubo Syndrome

Start: 2020-12-14End: 2028-12-31Target: 1000Updated: 2024-12-02

Related Papers

Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Blood2024-11-05

Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome

American Heart Journal2022-11-2331 citations